2016 - Sanofi

Skip to main content

December 8, 2016

Sanofi and Regeneron Announce Marketing Authorization Application for Dupixent® (dupilumab) Accepted for Review by the EMA

November 22, 2016

Sanofi Receives FDA Approval of Soliqua(TM) 100/33, for the Treatment of Adults with Type 2 Diabetes

November 17, 2016

Sanofi and Regeneron Announce Praluent® (alirocumab) Cardiovascular Outcomes Trial will Continue as Planned Following Interim Analysis

November 16, 2016

Sanofi and Regeneron Present Results from Phase 3 MONARCH Study of Investigational Sarilumab at American College of Rheumatology Annual Meeting

November 11, 2016

Sanofi Receives CHMP Recommendation for Approval of SuliquaTM in the EU

October 28, 2016

Sanofi : Sanofi and Regeneron Receive Complete Response Letter from FDA for Sarilumab, an Investigational Treatment for Rheumatoid Arthritis

October 28, 2016

Sanofi Announces Strong Q3 2016 Results

October 27, 2016

Sanofi Pasteur, Fiocruz, and WRAIR Agree to Collaborate on Zika Vaccine Research

October 12, 2016

Sanofi: Availability of the Pre-quarterly Results Communication

October 1, 2016

Sanofi and Regeneron Announce Positive Dupixent® (dupilumab) Phase 3 Atopic Dermatitis Data Published in The New England Journal of Medicine

September 30, 2016

Sanofi Appoints Alan Main to Executive Committee and Executive Vice President, Consumer HealthCare

September 26, 2016

Sanofi : BARDA Grants $43.2 million USD to Sanofi Pasteur for Zika

September 26, 2016

Sanofi and Regeneron Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA

September 19, 2016

Sanofi Files Suit in U.S. to Defend Paten Rights on Lantus® and Lantus® Solostar®

September 16, 2016

Sanofi: Treatment Effects Maintained Over Six Years in Patients with Relapsing Remitting Multiple Sclerosis who Received Sanofi Genzyme's Lemtrada® (alemtuzumab) in Clinical Trials

September 13, 2016

Sanofi's Fixed-Ratio Combination Helps More Patients Reach Mealtime Blood Sugar Target than Insulin Glargine Alone

September 12, 2016

Sanofi and Verily Life Sciences Announce Launch of Onduo, a Joint Venture to Develop Comprehensive Diabetes Management Platform

September 6, 2016

Sanofi : Sanofi Board of Directors Provides Update

September 6, 2016

Sanofi successfully prices EUR 3 billion bond issue

August 29, 2016

Sanofi and Regeneron Present Positive Phase 3 Investigational Data for Praluent® (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016

August 19, 2016

Sanofi Provides Update on New Drug Application for Investigational Once-Daily Fixed-Ratio Combination of Insulin Glargine and Lixisenatide

August 13, 2016

Sanofi: Dengue Immunization Public Program in Paraná State of Brazil Set To Achieve WHO 2020 Ambition

Sanofi Announces Q2 2016 Results

Sanofi Receives FDA Approval of AdlyxinTM for Treatment of Adults with Type 2 Diabetes

Sanofi: Availability of the Pre-quarterly Results Communication

Sanofi Pasteur Signs Research Agreement for Zika Vaccine

Sanofi Enters into Confidentiality Agreement with Medivation and Will be Provided Due Diligence Access and Confidential Information

Sanofi and Regeneron Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in Japan

Sanofi and Boehringer Ingelheim have reached definitive agreements to swap Sanofi's Animal Health and Boehringer Ingelheim's Consumer Healthcare businesses

Sanofi Announces Expiration of Hart-Scott-Rodino Waiting Period Regarding Proposed Acquisition of Medivation

Sanofi Files Definitive Consent Solicitation to Remove and Replace Medivation's Board

Sanofi Announces Positive Phase 3 Results for Investigational Titratable Fixed-Ratio Combination of Insulin Glargine and Lixisenatide

Sanofi Launches Action 2016, a Worldwide Employee Stock Purchase Plan

Sanofi Files Investor Presentation Regarding Proposed Acquisition of Medivation

Sanofi and Regeneron Announce that Dupilumab Used with Topical Corticosteroids (TCS) was Superior to Treatment with TCS Alone in Long-term Phase 3 Trial in Inadequately Controlled Moderate-to-Sever...

Sanofi Requests Record Date for Consent Solicitation to Remove and Replace Medivation's Board of Directors

Sanofi: FDA Advisory Committee Recommends Approval of Sanofi Treatment for Adults with Type 2 Diabetes

Sanofi Files Consent Solicitation To Remove and Replace Medivation's Board

Sanofi Announces Changes to Executive Committee Aligned to its Strategic Roadmap 2020

Sanofi Files for Hart-Scott-Rodino Notification Regarding Proposed Acquisition of Medivation

Sanofi Sends Letter to Medivation's Board of Directors

Sanofi: Annual General Shareholder Meeting of May 4, 2016

Sanofi Comments on Medivation's Rejection of Proposal

Sanofi: Solid Performance in the First Quarter of 2016 with Business EPS(1) up 5.3% at Constant Exchange Rates

Sanofi : Sanofi Offers to Acquire Medivation for $52.50 Per Share in Cash

Sanofi Invests €300 Million To Expand Biologics Site in Belgium

Strategic Advisory Group of Experts on Immunization Convened by the World Health Organization Recommends Use of Sanofi Pasteur's Dengue Vaccine in Endemic Countries

Sanofi: Availability of the Pre-quarterly Results Communication

Sanofi: World's First Public Dengue Immunization Program Starts in the Philippines

Sanofi and Regeneron Announce Positive Dupilumab Topline Results from Two Phase 3 Trials in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients

Sanofi successfully prices EUR 1.8 billion bond issue

Sanofi Appoints Dr. Yong-Jun Liu as Head of Research

Sanofi and Regeneron Announce Positive Topline Results from Phase 3 Praluent® (alirocumab) Study in Patients Undergoing LDL Apheresis Therapy

Sanofi and Regeneron Strongly Disagree with U.S. Jury Verdict in Ongoing Patent Litigation Regarding Praluent® (alirocumab) Injection and Will Appeal

Sanofi and DiCE Molecules Announce Research Collaboration to Discover Potential Therapeutics Based on Unique Small Molecule Discovery Platform

Sanofi and Regeneron Announce Topline Results of Phase 3 Monotherapy Study Demonstrating Superiority of Sarilumab vs. Adalimumab in Patients with Active Rheumatoid Arthritis

Sanofi Appoints Dr. Ameet Nathwani to Executive Committee and Executive Vice President, Group Chief Medical Officer

Sanofi Pasteur and MSD (Known as Merck in the United States and Canada) Announce Intent to End Joint Vaccines Operations in Europe, Sanofi Pasteur MSD, to Pursue Their Own Distinct Growth Strategies

Sanofi: Filing of the 2015 U.S. Form 20-F and French "Document de Référence" containing the Annual Financial Report

Sanofi Genzyme Presents Results from Phase 1/2 Study of Investigational Second-Generation Therapy for Pompe Disease

Sanofi's Board of Directors Proposes Appointment of Diane Souza and Thomas Südhof, MD as New Independent Directors

February 22, 2016

FDA Accepts Sanofi New Drug Application for Once-Daily Fixed-Ratio Combination of Insulin Glargine and Lixisenatide

February 9, 2016

Sanofi delivered 2015 business EPS up 8.5% on a reported basis and stable at constant exchange rates consistent with guidance

February 5, 2016

Sanofi Appoints Muzammil Mansuri to Executive Committee and Executive Vice President, Strategy & Business Development

February 2, 2016

Sanofi Pasteur to leverage its strong vaccine legacy in hunt for Zika vaccine

January 28, 2016

Sanofi and the Iran Ministry of Health and Medical Education Sign a Memorandum of Cooperation

January 14, 2016

Sanofi Pasteur Provides Key Support to the Human Vaccines Project

January 11, 2016

Sanofi and Warp Drive Bio to Collaborate on the Development of Novel Oncology Therapies and Antibiotics Based on Proprietary Platforms

January 11, 2016

Sanofi and Innate Pharma Collaborate on New Bispecific NK Cell Engagers in Immuno-Oncology

January 8, 2016

Sanofi and Regeneron Announce Sarilumab Biologics License Application Accepted for Review by US FDA

You are about to leave sanofi.com

If you wish to continue to this external website, click Proceed.

It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.

PROCEED